Amicus Therapeutics spins off genetic medicine unit in $600M SPAC deal

Amicus Therapeutics Inc., has unveiled plans to spinoff a “next-generation genetic medicine company” named Caritas Therapeutics.

Article from Philadelphia Business Journal